News Releases

Date Title and Summary View
June 5, 2021
– KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 5, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the...
Additional Formats
May 27, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 27, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a...
Additional Formats
May 10, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 10, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of an...
Additional Formats
May 3, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 3, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul...
Additional Formats
April 20, 2021
– KVD824 Phase 2 on Clinical Hold – – Planning for KVD900 Phase 3 Unaffected – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 20, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization...
Additional Formats
March 19, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 19, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has...
Additional Formats
March 11, 2021
– Recent KVD900 Phase 2 Clinical Trial Results Statistically and Clinically Significant – – IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 – – Following Upsized Public Offering, Funded to KVD900 NDA Filing – CAMBRIDGE, Mass....
Additional Formats
February 18, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 18, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in...
Additional Formats
February 16, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 16, 2021-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its common stock at a price to the public of $36.00 per share before...
Additional Formats
February 10, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 10, 2021-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share....
Additional Formats
Displaying 1 - 10 of 12